Evaluation of plant-produced humanized anti-ricin antibody


  1. Hu, W.-G.
  2. Hayward, S.
  3. Yin, J.
Corporate Authors
Defence Research and Development Canada, Suffield Research Centre, Ralston AB (CAN);Canada West Biosciences, Calgary ALTA (CAN)
Therapeutic antibodies can provide specific, instant, and consistent protection against infectious agents/toxins and therefore offer great value for the Canadian Armed Forces as an effective medical countermeasure (MedCM) against biological warfare agents. Unfortunately, therapeutic antibodies are among the most expensive drugs with an average cost of $300/gram when produced in mammalian cell lines. This production cost significantly impacts the development of antibodies as therapeutics. DRDC Suffield Research Centre has developed a highly effective humanized anti-ricin antibody, hD9. To reduce the manufacturing cost, the production of hD9 was explored in plants and purified hD9 was produced in the genetically engineered tobacco-like plants by PlantForm Corporation. In this report, plant-produced hD9 (PhD9) was compared to its mammalian cell-produced counterpart, hD9 to investigate whether the plant manufacturing process would affect the antibody’s ricin-binding affinity and anti-ricin potency. In a ricin-binding affinity assay, a cell-based ricin neutralization assay and in a systemic ricin intoxication mouse model, PhD9 demonstrated its ricin-binding affinity and anti-ricin potency to be comparable to hD9, indicating that plants can be used as bioreactors for cost-effective and large-scale production of functional PhD9. Additionally, PhD9 was further compared both in vitro and in vivo with the UK Defence Science and Technology Laboratory (Dstl)-developed sheep anti-ricin

Il y a un résumé en français ici.

therapeutic antibodies;anti-ricin;plant-produced;efficacy
Report Number
DRDC-RDDC-2016-R235 — Scientific Report
Date of publication
01 Nov 2016
Number of Pages
Electronic Document(PDF)

Permanent link

Document 1 of 1

Date modified: